Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
3
×
boston blog main
boston top stories
clinical trials
3
×
fda
3
×
hereditary transthyretin amyloidosis
3
×
life sciences
national blog main
national top stories
patisiran
rna interference
akcea therapeutics
biotech
inotersen
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
vyndaqel
alexion pharmaceuticals
andrew fire
barry greene
boehringer ingelheim
boston university
craig mello
dan ollendorf
deals
dicerna pharamceuticals
drugs
hepatitis b
hepatitis b virus
john berk
john maraganore
mary o'donnell
nobel prize
onpattro
What
alnylam
drug
fda
medicine
pharmaceuticals
afternoon
ago
alnylam’s
approve
approved
awaits
biological
caught
causing
crossed
decades
decision
dicerna
discovered
disease
eye
fingers
friday
gene
gets
hepatitis
historic
history
intended
landmark
making
medicines
ok
onpattro
patients
patisiran
pay
pharma
producing
protein
Language
unset
Current search:
boston
×
" clinical trials "
×
fda
×
" hereditary transthyretin amyloidosis "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision